Labcorp (NYSE:LH – Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to post earnings of $4.64 per share and revenue of $3.76 billion for the quarter. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 9:00 AM ET.
Labcorp (NYSE:LH – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, topping the consensus estimate of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The business had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. During the same period last year, the firm earned $4.35 earnings per share. The company’s quarterly revenue was up 5.8% on a year-over-year basis. On average, analysts expect Labcorp to post $18.32 EPS for the current fiscal year and $19.69 EPS for the next fiscal year.
Labcorp Stock Performance
NYSE:LH opened at $329.51 on Tuesday. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. Labcorp has a 12-month low of $244.52 and a 12-month high of $341.80. The stock has a 50-day moving average price of $320.76 and a 200 day moving average price of $285.21. The stock has a market capitalization of $26.72 billion, a P/E ratio of 18.81, a P/E/G ratio of 1.88 and a beta of 0.87.
Labcorp Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp’s payout ratio is 23.82%.
Analyst Ratings Changes
Several research firms have commented on LH. Bank of America increased their price objective on shares of Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Barclays boosted their target price on shares of Labcorp from $320.00 to $330.00 and gave the stock an “equal weight” rating in a report on Friday, September 11th. Weiss Ratings upgraded shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday, October 21st. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $306.00 price target on shares of Labcorp in a report on Friday, July 31st. Finally, Mizuho set a $355.00 price target on shares of Labcorp in a report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $337.73.
Get Our Latest Stock Report on Labcorp
Insider Buying and Selling
In other Labcorp news, EVP Amy B. Summy sold 924 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total value of $283,427.76. Following the completion of the sale, the executive vice president directly owned 6,956 shares in the company, valued at approximately $2,133,683.44. This represents a 11.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Adam H. Schechter sold 4,669 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the completion of the sale, the chief executive officer directly owned 102,565 shares of the company’s stock, valued at approximately $32,858,749.05. This trade represents a 4.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,593 shares of company stock valued at $2,733,295 in the last 90 days. Company insiders own 0.84% of the company’s stock.
Labcorp Company Profile
Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.
Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.
Read More
- Five stocks we like better than Labcorp
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
